BeOne Medicines AG (NASDAQ: ONC) Stock Competitors & Peer Comparison

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while VRTX trades at $546.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas VRTX's P/E ratio is 28.70. In terms of profitability, ONC's ROE is +0.14%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ONC is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check VRTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, REGN has a market cap of 85.3B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while REGN trades at $827.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas REGN's P/E ratio is 18.14. In terms of profitability, ONC's ROE is +0.14%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ONC is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check REGN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ONC's ROE is +0.14%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ONC is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check VRNA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ARGX trades at $1,033.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ARGX's P/E ratio is 93.24. In terms of profitability, ONC's ROE is +0.14%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ONC is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARGX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MRNA has a market cap of 57.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MRNA trades at $145.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MRNA's P/E ratio is -17.86. In terms of profitability, ONC's ROE is +0.14%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MRNA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RVMDW trades at $11.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RVMDW's P/E ratio is -1.65. In terms of profitability, ONC's ROE is +0.14%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ONC is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RVMDW's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RVMD has a market cap of 44.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RVMD trades at $210.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RVMD's P/E ratio is -23.81. In terms of profitability, ONC's ROE is +0.14%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ONC is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RVMD's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ONC's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ONC is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check SGEN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ALNY trades at $266.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ALNY's P/E ratio is 47.95. In terms of profitability, ONC's ROE is +0.14%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ONC is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ALNY's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, INSM has a market cap of 27.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while INSM trades at $126.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas INSM's P/E ratio is -30.73. In terms of profitability, ONC's ROE is +0.14%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check INSM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BNTX has a market cap of 26.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BNTX trades at $103.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BNTX's P/E ratio is -13.46. In terms of profitability, ONC's ROE is +0.14%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BNTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, INCY has a market cap of 25.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while INCY trades at $126.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas INCY's P/E ratio is 17.04. In terms of profitability, ONC's ROE is +0.14%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ONC is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check INCY's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ROIV trades at $34.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ROIV's P/E ratio is -33.23. In terms of profitability, ONC's ROE is +0.14%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ONC is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ROIV's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, UTHR has a market cap of 20.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while UTHR trades at $487.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas UTHR's P/E ratio is 17.45. In terms of profitability, ONC's ROE is +0.14%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ONC is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check UTHR's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, GMAB has a market cap of 20.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while GMAB trades at $33.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas GMAB's P/E ratio is 25.32. In terms of profitability, ONC's ROE is +0.14%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ONC is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ONC.Check GMAB's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ONC's ROE is +0.14%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ONC is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BGNE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ONC is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNA-WT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ASND trades at $270.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ASND's P/E ratio is -111.80. In terms of profitability, ONC's ROE is +0.14%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ONC is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ASND's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while NBIX trades at $155.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas NBIX's P/E ratio is 22.49. In terms of profitability, ONC's ROE is +0.14%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ONC is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check NBIX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while JAZZ trades at $246.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas JAZZ's P/E ratio is 9.23. In terms of profitability, ONC's ROE is +0.14%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ONC is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ONC.Check JAZZ's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while EXEL trades at $59.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas EXEL's P/E ratio is 16.86. In terms of profitability, ONC's ROE is +0.14%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ONC is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ONC.Check EXEL's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BBIO trades at $74.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BBIO's P/E ratio is -20.01. In terms of profitability, ONC's ROE is +0.14%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ONC is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BBIO's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while SMMT trades at $17.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas SMMT's P/E ratio is -15.72. In terms of profitability, ONC's ROE is +0.14%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ONC is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SMMT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while HALO trades at $110.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas HALO's P/E ratio is 20.56. In terms of profitability, ONC's ROE is +0.14%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ONC is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ONC.Check HALO's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BMRN trades at $66.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BMRN's P/E ratio is 31.99. In terms of profitability, ONC's ROE is +0.14%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ONC is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BMRN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ONC's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ONC is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check KRTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MDGL trades at $541.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MDGL's P/E ratio is -42.27. In terms of profitability, ONC's ROE is +0.14%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ONC is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MDGL's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ARWR trades at $86.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ARWR's P/E ratio is -38.37. In terms of profitability, ONC's ROE is +0.14%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ONC is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARWR's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TECH trades at $72.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TECH's P/E ratio is 37.34. In terms of profitability, ONC's ROE is +0.14%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ONC is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TECH's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ONC's ROE is +0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ONC is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RNAM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while AXSM trades at $206.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas AXSM's P/E ratio is -53.96. In terms of profitability, ONC's ROE is +0.14%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ONC is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check AXSM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while KRYS trades at $358.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas KRYS's P/E ratio is 44.89. In terms of profitability, ONC's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KRYS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PRAX has a market cap of 9.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PRAX trades at $351.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PRAX's P/E ratio is -27.21. In terms of profitability, ONC's ROE is +0.14%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ONC is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRAX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while KYMR trades at $117.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas KYMR's P/E ratio is -36.68. In terms of profitability, ONC's ROE is +0.14%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ONC is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KYMR's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, IONS has a market cap of 9.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while IONS trades at $58.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas IONS's P/E ratio is -33.77. In terms of profitability, ONC's ROE is +0.14%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IONS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ONC's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RXDX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PTGX trades at $145.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PTGX's P/E ratio is 141.48. In terms of profitability, ONC's ROE is +0.14%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ONC is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PTGX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ONC's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ONC is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ONC.Check NUVL's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CYTK trades at $72.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CYTK's P/E ratio is -10.07. In terms of profitability, ONC's ROE is +0.14%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ONC is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CYTK's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ONC's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ONC is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CRNX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PCVX trades at $61.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PCVX's P/E ratio is -8.02. In terms of profitability, ONC's ROE is +0.14%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ONC is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PCVX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ONC's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ONC is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check IMGN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TGTX trades at $55.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TGTX's P/E ratio is 20.28. In terms of profitability, ONC's ROE is +0.14%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ONC is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TGTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while IBRX trades at $8.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas IBRX's P/E ratio is -8.33. In terms of profitability, ONC's ROE is +0.14%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ONC is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IBRX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ABVX trades at $114.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ABVX's P/E ratio is -60.17. In terms of profitability, ONC's ROE is +0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ONC is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ABVX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ONC's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BPMC's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas APGE's P/E ratio is -31.19. In terms of profitability, ONC's ROE is +0.14%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ONC is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APGE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CERE's P/E ratio is -16.47. In terms of profitability, ONC's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ONC is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CERE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while IMVT trades at $39.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas IMVT's P/E ratio is -13.92. In terms of profitability, ONC's ROE is +0.14%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ONC is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IMVT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TXG has a market cap of 8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TXG trades at $62.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TXG's P/E ratio is -106.19. In terms of profitability, ONC's ROE is +0.14%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TXG's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TWST trades at $124.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TWST's P/E ratio is -56.18. In terms of profitability, ONC's ROE is +0.14%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ONC is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TWST's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, BLTE has a market cap of 7.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while BLTE trades at $193.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas BLTE's P/E ratio is -103.53. In terms of profitability, ONC's ROE is +0.14%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ONC is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BLTE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while SYRE trades at $88.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas SYRE's P/E ratio is -45.63. In terms of profitability, ONC's ROE is +0.14%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SYRE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ONC's ROE is +0.14%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ONC is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MTSR's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CAI trades at $25.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CAI's P/E ratio is 70.44. In terms of profitability, ONC's ROE is +0.14%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CAI's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RYTM trades at $102.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RYTM's P/E ratio is -33.04. In terms of profitability, ONC's ROE is +0.14%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RYTM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ONC's ROE is +0.14%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ONC is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRUS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ONC's ROE is +0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ONC is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ACLX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while SRRK trades at $55.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas SRRK's P/E ratio is -16.04. In terms of profitability, ONC's ROE is +0.14%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ONC is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SRRK's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CGON trades at $74.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CGON's P/E ratio is -27.76. In terms of profitability, ONC's ROE is +0.14%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ONC is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CGON's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RETA's P/E ratio is -66.29. In terms of profitability, ONC's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ONC is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RETA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ONC's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ONC is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CNTA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MIRM trades at $100.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MIRM's P/E ratio is -6.93. In terms of profitability, ONC's ROE is +0.14%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ONC is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MIRM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TVTX trades at $65.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TVTX's P/E ratio is -145.07. In terms of profitability, ONC's ROE is +0.14%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ONC is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TVTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while DNTH trades at $108.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas DNTH's P/E ratio is -26.05. In terms of profitability, ONC's ROE is +0.14%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ONC is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNTH's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while COGT trades at $34.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas COGT's P/E ratio is -16.47. In terms of profitability, ONC's ROE is +0.14%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ONC is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check COGT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PTCT trades at $69.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PTCT's P/E ratio is -29.74. In terms of profitability, ONC's ROE is +0.14%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ONC is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PTCT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while XENE trades at $59.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas XENE's P/E ratio is -12.71. In terms of profitability, ONC's ROE is +0.14%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ONC is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check XENE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while LGND trades at $285.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas LGND's P/E ratio is 31.35. In terms of profitability, ONC's ROE is +0.14%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ONC is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ONC.Check LGND's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ERAS trades at $16.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ERAS's P/E ratio is -17.41. In terms of profitability, ONC's ROE is +0.14%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ERAS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ONC's ROE is +0.14%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ONC is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CDTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ORKA trades at $92.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ORKA's P/E ratio is -47.69. In terms of profitability, ONC's ROE is +0.14%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ONC is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ORKA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ONC's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ONC is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ABCM's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ONC's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ONC is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ISEE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CRSP trades at $55.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CRSP's P/E ratio is -11.72. In terms of profitability, ONC's ROE is +0.14%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CRSP's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas APLS's P/E ratio is 38.35. In terms of profitability, ONC's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ONC is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APLS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while DFTX trades at $38.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas DFTX's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ONC is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DFTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ACAD trades at $28.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ACAD's P/E ratio is 12.62. In terms of profitability, ONC's ROE is +0.14%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ONC is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ACAD's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TERN's P/E ratio is -51.41. In terms of profitability, ONC's ROE is +0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ONC is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TERN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PBLS has a market cap of 4.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PBLS trades at $40.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PBLS's P/E ratio is -45.93. In terms of profitability, ONC's ROE is +0.14%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ONC is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PBLS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CELC trades at $95.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CELC's P/E ratio is -22.26. In terms of profitability, ONC's ROE is +0.14%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ONC is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CELC's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while EWTX trades at $43.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas EWTX's P/E ratio is -23.28. In terms of profitability, ONC's ROE is +0.14%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check EWTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ONC's ROE is +0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ONC is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ONC.Check FOLD's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, DYN has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while DYN trades at $24.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas DYN's P/E ratio is -7.54. In terms of profitability, ONC's ROE is +0.14%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ONC is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DYN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ONC's ROE is +0.14%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ONC is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ONC.Check AKRO's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ONC's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ONC is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ALPN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ELVN trades at $59.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ELVN's P/E ratio is -35.52. In terms of profitability, ONC's ROE is +0.14%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ONC is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ELVN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas OPT's P/E ratio is -1.52. In terms of profitability, ONC's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ONC is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ONC.Check OPT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ONC's ROE is +0.14%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ONC is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRTC's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while RLAY trades at $19.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas RLAY's P/E ratio is -12.13. In terms of profitability, ONC's ROE is +0.14%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ONC is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RLAY's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ONC's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ONC is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while MANE trades at $98.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas MANE's P/E ratio is -31.34. In terms of profitability, ONC's ROE is +0.14%, compared to MANE's ROE of -0.29%. Regarding short-term risk, ONC is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MANE's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while VKTX trades at $34.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas VKTX's P/E ratio is -7.48. In terms of profitability, ONC's ROE is +0.14%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ONC is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check VKTX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TLX trades at $11.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TLX's P/E ratio is 124.63. In terms of profitability, ONC's ROE is +0.14%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ONC is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TLX's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while LEGN trades at $21.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas LEGN's P/E ratio is -31.65. In terms of profitability, ONC's ROE is +0.14%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check LEGN's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, IOVA has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while IOVA trades at $8.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas IOVA's P/E ratio is -12.04. In terms of profitability, ONC's ROE is +0.14%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ONC is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IOVA's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, TARS has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while TARS trades at $90.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas TARS's P/E ratio is -83.28. In terms of profitability, ONC's ROE is +0.14%, compared to TARS's ROE of -0.14%. Regarding short-term risk, ONC is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TARS's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while ADPT trades at $24.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas ADPT's P/E ratio is -59.22. In terms of profitability, ONC's ROE is +0.14%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ONC is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ADPT's competition here

BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONC stands at 38.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $358.26 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONC currently has a P/E ratio of 63.04, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ONC's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ONC is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CPRX's competition here